Phase 2 N=41 Catheter Related - Gram Positive Bloodstream Infections
Bloodstream Infection
Primary: Clinical Response Within 48 Hours — 28 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1,088 Reducing Catheter-Related Bloodstream Infections in the ICU With a Chlorhexidine-Impregnated Sponge (BIOPATCH)
Catheter-related Bloodstream Infection
Primary: The Number of Catheter Related Bloodstream Infections (BSI) /1000 Catheter Days in Both Arms — 4.74; 4.72 BSIs /1000 catheter days — p=0.05
Phase 2 N=61 Multifaceted Treatment of Catheter-related Urinary Tract Infection
Spinal Cord Injury · Neurogenic Bladder · Urinary Tract Infection
Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…
N/A N=1,209 Reduction of Catheter-associated Urinary Tract Infection With a Daily Nursing Review of the Indication
Urinary Tract Infections · Urinary Tract; Accessory
Primary: Rate of Catheter-associated Urinary Tract Infection — 10; 12 infections per 1000 days
Phase 2 N=99 Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion
Urinary Tract Infections · Catheter Infection · Catheter-Related Infections
Primary: Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI) — 7; 6 Participants
N/A N=165 Passive Disinfection Cap Compliance Study
Infection, Hospital
Primary: Disinfecting Barrier Cap Compliance — 98.43 percentage of connector with compliance
N/A N=701 Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
End Stage Renal Disease (ESRD)
Primary: Positive Blood Cultures (PBC's) Per 1,000 Central Venous Catheter (CVC)-Days — 0.28; 0.75 PBCs per 1,000 CVC-days
N/A N=149 Hub Cleansing to Prevent Hub Infection
Bacteremia
Primary: Number of Central Venous Catheter Hubs With Internal Contamination — 42; 18; 39; 14 contaminated hubs
N/A N=100 Modified Reporting From Indwelling Catheters
Urinary Tract Infections
Primary: Number of Participants With Appropriate Treatment — 31; 23 Participants — p=0.45
N/A N=16 Community Central Line Infection Prevention Trial
Infection
Primary: Total Number of Central Line Associated Blood Stream Infections (CLABSI) — 113; 84; 123; 109 infections
N/A N=20 Reduction of Bacteriuria in Subjects Practicing Intermittent Catheterization
Bacteriuria
Primary: Total Bacteria Count Change From Baseline and After 24 Hours. — -62519; 57448 CFU/mL — p=0.6250
N/A N=433 A Registry for Comparing Catheter-Related Infection Rates Among Various Shunt Systems in the Treatment of Hydrocephalus
Hydrocephalus
Primary: Number of Subjects With Shunt Infections — 14 participants
N/A N=1,229 Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
End Stage Renal Disease (ESRD)
Primary: Positive Blood Cultures (PBCs) Per 1,000 Central Venous Catheter (CVC)-Days — 0.26; 0.59 PBCs per 1,000 CVC-days
N/A N=50 Bactiseal Catheter Safety Registry in China
Hydrocephalus
Primary: 50 Participants With Non-infection Within One Year — 1 Participants
Phase 2 N=20 t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection
Central Venous Catheter Thrombosis · Central Venous Catheter Associated Bloodstream Infection
Primary: Catheter-associated Venous Thrombosis — 3; 3 Participants
N/A N=101 Observational Study of Complications Related to Use of Peripherally Inserted Central Catheters
Adult Patients With Peripherally Inserted Central Catheters
Primary: Rate of PICC Line Occlusions — 37 percentage of enrolled subjects
Phase 3 N=806 Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
Kidney Failure, Chronic · Catheter-Related Infections
Primary: Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD)…
Phase 1 N=10 Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study
Urinary Tract Infection
Primary: Rate of UTI While Colonized With E. Coli 83972. — 8.5 UTIs per 1000 patient-days
N/A N=53 Chlorhexidine Dressings for Hemodialysis Catheter Exit Site Care: Comparative Study
Hemodialysis Catheter Infection
Primary: Bacteraemia Rate — 2; 1 episodes — p=1.00
N/A N=500 Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Bloodstream Infection · Sepsis Bacterial · MRSA Bacteremia
Primary: Time to Last Dose of Intravenous Vancomycin — 19.0; 12.5 time in hours
Phase 4 N=27 Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
Leukemia · Lymphoma · Blood Disorders
Primary: Length of Stay (LOS) in Those With 14 Confirmed Catheter Related Infection Cases — 124; 208 HOURS
N/A N=9,891 Efficacy of a Prepackaged Cleansing Cloth and Standardized Cleansing Protocol for Catheter Care at Reducing CAUTI Rates
Catheter-Associated Urinary Tract Infection
Primary: Infections Per 1,000 (CAUTI) Days — 0.8429 infection per 1,000 catheter days
Phase 2 N=509 Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
Bacteremia
Primary: Cure Rate — 207; 209 Participants
N/A N=152 Complications Associated With Central Venous Access in the NSICU: PICC vs CVC
PICC · Central Venous Catheter · Central Line
Primary: Participants With Complications With Central Access Including Insertion — 14; 10 Participants — p=0.271
N/A N=295 Study to Estimate the Point Prevalence of Peripheral Intravenous Catheter-related Complications in Brazil
Infusion Site Injury
Primary: Percentage of PIVCs Sites With at Least One Clinical or Mechanical Complication (PIVC-related Complications) — 10; 6; 7 percentage of PIVC sites
N/A N=217 Central Venous Access Study
Central Line Catheters
Primary: Adherence to Clinical Guidelines for Catheter Interventions and Management — 12; 0; 0; 11 # of catheter-related incidents
N/A N=212 Midlines and Thrombophlebitis
Catheter Infection · Catheter Thrombosis · Catheter Complications
Primary: Upper Extremity CR-UEVT — 7; 11 Participants
Phase 3 N=177 Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
Bacterial Infection · Benign Neoplasm · Malignant Neoplasm
Primary: Central Line-associated Bloodstream Infections (CLABSI) Events During the At-risk Days — 5.44; 3.1 CLABSI per 1000 at-risk days.
Phase 4 N=434 Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System
Intraventricular Hemorrhage · Subarachnoid Hemorrhage
Primary: Number of Infections — 4; 5; 4; 5 Infections
N/A N=60 Safe Critical Care: Testing Improvement Strategies
Central Line-associated Bloodstream Infection (CLABSI) · Ventilator Associated Pneumonia
Primary: CLABSI and VAP Rates — 1.84; 2.42; 2.24; 2.47 events/1000 device days — p=<.05